Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-11-13
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT00072865
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saint Petersburg, Russia, Russian Federation
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 94
- Registration Number
- NCT00003141
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 30
- Registration Number
- NCT00072384
- Locations
- 🇺🇸
University of Illinois, Chicago, Illinois, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
- Conditions
- Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaHepatosplenic T-cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaSmall Intestine LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaSplenic Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2017-06-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT00072514
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 78
- Registration Number
- NCT00072527
- Locations
- 🇺🇸
McDonough District Hospital, Macomb, Illinois, United States
🇺🇸Hudner Oncology Center at Saint Anne's Hospital, Fall River, Massachusetts, United States
🇺🇸Saint Luke's Hospital, Chesterfield, Missouri, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-11-04
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 36
- Registration Number
- NCT00004093
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
- Conditions
- First Posted Date
- 2003-10-16
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Genzyme, a Sanofi Company
- Registration Number
- NCT00071188
- Locations
- 🇹🇭
Research Site, Chiang mai, Thailand
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma
- Conditions
- Interventions
- Biological: filgrastimBiological: sargramostimDrug: carboplatinDrug: cisplatinDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: etoposide phosphateDrug: ifosfamideDrug: isotretinoinDrug: melphalanDrug: thiotepaDrug: vincristine sulfateProcedure: conventional surgeryProcedure: peripheral blood stem cell transplantationRadiation: radiation therapy
- First Posted Date
- 2003-10-09
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 42
- Registration Number
- NCT00017368
- Locations
- 🇺🇸
CCOP - Columbia River Oncology Program, Portland, Oregon, United States
🇺🇸Floating Hospital for Children, Boston, Massachusetts, United States
🇺🇸CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States
Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 140
- Registration Number
- NCT00070486
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, United States
🇺🇸Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States
🇺🇸CCOP - North Shore University Hospital, Manhasset, New York, United States
Phase II CT-2103/Carboplatin in Ovarian Cancer
- Conditions
- First Posted Date
- 2003-10-06
- Last Posted Date
- 2008-09-22
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 82
- Registration Number
- NCT00069901
- Locations
- 🇺🇸
Baptist Regional Cancer Center, Knoxville, Tennessee, United States
🇺🇸Resource Center for Gynecology/ Oncology, Kansas City, Missouri, United States
🇺🇸California Cancer Care, Greenbrae, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.